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Natural Killer (NK) cells play a key role in cancer immunosurveillance. However, NK cells
from cancer patients display an altered phenotype and impaired effector functions. In
addition, evidence of a regulatory role for NK cells is emerging in diverse models of viral
infection, transplantation, and autoimmunity. Here, we analyzed clear cell renal cell
carcinoma (ccRCC) datasets from The Cancer Genome Atlas (TCGA) and observed
that a higher expression of NK cell signature genes is associated with reduced survival.
Analysis of fresh tumor samples from ccRCC patients unraveled the presence of a high
frequency of tumor-infiltrating PD-L1+ NK cells, suggesting that these NK cells might
exhibit immunoregulatory functions. In vitro, PD-L1 expression was induced on NK cells
from healthy donors (HD) upon direct tumor cell recognition through NKG2D and was
further up-regulated by monocyte-derived IL-18. Moreover, in vitro generated PD-L1hi NK
cells displayed an activated phenotype and enhanced effector functions compared to
PD-L1- NK cells, but simultaneously, they directly inhibited CD8+ T cell proliferation in a
PD-L1-dependent manner. Our results suggest that tumors might drive the development
of PD-L1-expressing NK cells that acquire immunoregulatory functions in humans. Hence,
rational manipulation of these regulatory cells emerges as a possibility that may lead to
improved anti-tumor immunity in cancer patients.
Keywords: NK cells, PD-L1, CD8+ T cells, regulation, renal cell carcinomaINTRODUCTION
Natural killer (NK) cells represent the cytotoxic lineage of innate lymphoid cells (ILC) (1) and play a
pivotal role as effector cells against tumors and virus-infected cells. NK cell activation, which is
controlled by the balance of signals elicited by a plethora of inhibitory and activating receptors,
results in a cytotoxic response and the production of inflammatory cytokines, such as interferon-gorg September 2021 | Volume 12 | Article 7459391
Sierra et al. PD-L1 in Tumor-Experienced NK Cells(IFN-g) and tumor necrosis factor (TNF) (2, 3). Although NK
cells are critical for the elimination of nascent tumor cells (4, 5),
during the equilibrium phase (dormancy) between the tumor
and the immune system NK cells seem to be dispensable (6).
Moreover, once tumors escape from the immune system through
a broad spectrum of immunosuppressive strategies that result in
clinically apparent malignancies (7), tumor-infiltrating NK cells
(TINK) become dysfunctional and display phenotypic
alterations (8–13).
Recent observations demonstrated a regulatory role for NK
cells in diverse models of viral infect ion (14–17),
transplantation (18) and autoimmunity (19). For example,
NK cells can limit T cell responses through multiple
mechanisms, including NK cell-mediated killing of activated
CD8+ T cells (16, 17, 20–23), CD4+ T cells (20, 21, 24, 25) and
dendritic cells (14, 26, 27). In the context of chronic viral
infections and other immunopathological conditions, such
regulatory activity of NK cells may contribute to T cell
homeostasis. Accordingly, some patients with autoimmune
disorders display reduced NK cell numbers with impaired
cytotoxicity (28). However, evidence about a regulatory
function of NK cells during tumor growth remains poorly
explored (29). In this context, we have recently identified a
subset of Programmed Death-Ligand 1 (PD-L1)-expressing NK
cells, that arise in tumor bearing mice which can inhibit tumor-
specific CD8+ T cell priming (30).
PD-L1 is a suppressive molecule expressed on diverse
hematopoietic and nonhematopoietic cells that contributes to
maintain T cell homeostasis (31). However, PD-L1 is also up-
regulated on tumor cells which contributes to the evasion of the
immune response (31). Its receptor, PD-1, is up-regulated on
activated T cells, and functions as a co-inhibitory molecule
during T cell–mediated immunity (32). Targeted blockade of
PD-1/PD-L1 using specific monoclonal antibodies (mAb) can
restore T cell function and enhance antitumor immunity,
promoting clinically unparalleled responses in different types
of tumors (33, 34). Although tumor expression of PD-L1 seems
to be the main driver for immune suppression, several studies
showed that PD-L1 expressed by non-tumor cells including
myeloid-derived cells, regulatory T cells and endothelial cells
also mediate T cell disfunction (35–39). However, the expression
of PD-L1 on human NK cells, its regulation and function remain
ill-defined.
Here we show that the presence of a high expression of NK
cell-associated signature genes in clear cell renal cell carcinoma
(ccRCC) datasets -which account for 75% off all RCC (40)- from
The Cancer Genome Atlas (TCGA) is associated with a worsened
outcome. Also, ccRCC tumor samples, exhibited a high
frequency of PD-L1+ TINK. PD-L1 expression was induced on
NK cells after direct interaction with tumor cells and enhanced
by monocyte-derived IL-18. Also, although PD-L1+ NK cells
retained their effector functions, they inhibited CD8 T cell
proliferation through PD-L1. Our results indicate that tumors
drive the expansion of PD-L1-expressing NK cells with
immunoregulatory functions. Accordingly, targeting ofFrontiers in Immunology | www.frontiersin.org 2regulatory NK cells emerges as a possibility that may lead to
the reinvigoration of anti-tumor immunity.MATERIAL AND METHODS
Bioinformatic Analysis
The online tool GEPIA2 [Gene Expression Profiling Interactive
Analysis, http://gepia2.cancer-pku.cn/#survival (41)] was used to
analyze RNA-Seq data from TCGA. Kidney Renal Clear Cell
Carcinoma (KIRC, n=516) dataset was used to perform a
Kaplan-Meier analysis of the effect of NK cell infiltration on
disease-free survival and overall survival. NK cell infiltration was
assesses based on expression of a multi-gene signature that
includes 10 NK cell-associated genes (NCR1, XCL1, XCL2,
NCAM1, NCR3, IL18RAP, KIR2DL4, KLRC3, KLRD1 and
NCR2; 42–45). For the analysis, patients were separated in two
groups: those with a high NK cell infiltration (presence of high
abundance of this NK cell signature, top quartile) and those with
a low NK cell infiltration (presence of low abundance of this NK
cell signature, bottom quartile). Differences between groups were
analyzed with log-rank (Mantel-Cox) test and the hazard ratio
(HR) was estimated using a Cox proportional hazards model
in GEPIA2.
Human Samples
Blood and tumor biopsies were obtained from treatment-naïve
ccRCC patients undergoing partial or radical nephrectomy in
two urology services (CEMIC and Hospital Alemán, Buenos
Aires), at the time of surgery. Buffy coats from healthy donors
(HD) were provided by the Hospital Churruca-Visca (Buenos
Aires). The characteristics of the patients are listed in
Supplementary Table 1. This study was conducted according
to the guidelines of the Declaration of Helsinki and approved by
the Institutional Ethics Committee of IBYME (protocol CE003-
03/2014, date of approval: March 20, 2014). Also written
informed consent of participating subjects was obtained.
Cells and Cultures
The NK cell-sensitive K562 cell line and the human ccRCC cell
line 786-O were obtained from ATCC. The RCC cell line SN12c
was kindly provided by Dr. Gabriel Fiszman (Instituto de
Oncologıá Angel H. Roffo, Buenos Aires). Cells were cultured
in RPMI 1640 (Thermo-Fischer) supplemented with 10%
inactivated FBS (Thermo-Fischer), sodium pyruvate (Fluka),
glutamine (Sigma-Aldrich) and antibiotics (Sigma-Aldrich),
and kept at 37°C in 5% CO2.
Cell Separation
Peripheral blood mononuclear cells (PBMC) were obtained by
Ficoll-Paque™ Plus (GE Life Sciences) centrifugation of the
blood samples. Monocytes (CD14+ cells) were isolated by
MACS (Miltenyi); NK cells and T cells were isolated using
RosetteSep (StemCell) and Ficoll-Paque™ Plus centrifugation.
Purity of isolated cells was always above 90%, as assessed by flowSeptember 2021 | Volume 12 | Article 745939
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cells) or CD3+ cells (T cells).
Flow Cytometry and Cell Sorting
Non-specific staining was blocked with 10% normal mouse
serum. Cells were labeled according to the experiment with the
following Ab: APC anti-CD56 (clone N901) from Beckman
Coulter; PE and FITC anti-CD3 (clone UCHT1), FITC anti-
CD14 (clone M5E2), PE/Cy7 anti-PD-L1 (clone 29E.2A3), PE
anti-CD25 (clone BC96), PE anti-IL-18Ra (clone H44), FITC
anti-CD69 (clone FN50), PE anti-IFN-g (clone 4S.B3), Brilliant
Violet 421 anti-CD107a (clone H4A3), PE anti-FasL (clone
NOK-1), PerCP/Cy5-5 anti-CD34 (clone 581), APC/Cy7 anti-
CD45 (clone H130) from BioLegend; AlexaFluor 488 anti-
TRAIL (clone 75402) from R&D Systems; APC and violetFluor
450 anti-CD3 (clone UCHT1) and PE/Cy7 anti-CD8 (clone
RPA-T8) from Tonbo Biosciences. Cell viability was
determined with ZombieAqua from BioLegend. For cell
sorting, PBMC were cultured 48 h alone or with K562 cells,
stained with anti-CD3 and anti-CD56 mAb, and thereafter NK
cells (CD3-CD56+ cells) were sorted in a FACSAria II-plus cell
sorter (BD Bioscience) with a purity of 95–98%. For TINK
staining, single cell suspensions from freshly dissected tumors
were prepared by mechanical dissociation and filtration through
nylon mesh. Cell suspensions were exhaustively washed and
stained for CD34, CD45, CD3, CD56, PD-L1 and ZombieAqua.
PD-L1 express ion was ana lyzed on l ive NK cel l s
(ZombieAqualowCD45+CD34-CD3-CD56+ cells) following the
gating strategy depicted in Supplementary Figure 1.
Fluorescence Minus One (FMO) was used to establish the gate
for the PD-L1- and PD-L1+ populations. Expression of IFN-gwas
analyzed by intracellular flow cytometry using FOXP3 Fix/Perm
buffer and FOXP3 Perm buffer (BioLegend). For assessment of
IFN-g production and degranulation (CD107a), cells were
cultured in the presence of Monensin and Brefeldin A
(BioLegend) during the last 5 h of culture and analyzed by
flow cytometry. Samples were acquired in a FACSCanto II-plus
flow cytometer (BD Biosciences), a MACSQuant10 or a
MACSQuant16 Analyzer (Miltenyi Biotec) and data analysis
was conducted with FlowJo software (BD Biosciences). Results
were expressed as geometric mean fluorescence intensity (MFI)
or as percentage of positive cells.
In Vitro PD-L1 Expression
5x105 PBMC or 1x105 NK cells isolated fromHDwere cultured in
the absence (medium) or in the presence of 3x105 tumor cells for
48 h, stained for CD3, CD56 and PD-L1, and analyzed by flow
cytometry following the gating strategy depicted in
Supplementary Figure 2. For blocking experiments, anti-IL-12
p70 (10 mg/ml, clone QS-12p70, Abcam), anti-IL-15 (10 mg/ml,
clone ct2nu, eBioscience), anti-IL-18 (10 mg/ml, clone 125-2H,
MBL International), anti-IFN-g (10 mg/ml, clone NIB42,
BioLegend), anti-IFN-gR (10 mg/ml, clone GIR-208, BioLegend)
or anti-NKG2D (20 mg/ml, clone 1D11, BioLegend) mAb, were
added at the beginning of the cocultures. In other experiments,
recombinant IFN-g (200 ng/ml, Peprotech) and recombinant
IL-18 (10 ng/ml, MBL International) were used to stimulateFrontiers in Immunology | www.frontiersin.org 3cells. In some experiments, 1x105 autologous monocytes were
added to NK cell cultures.
ELISA
Detection of biologically active IL-18 in culture supernatants was
performed using the anti-human IL-18 matched pair of mAb
clone 125-2H and biotinylated clone 159-12B (MBL
International), and HRP-labeled streptavidin (BioLegend).
T-Cell Proliferation Assay
CFSE-labeled T cells (5 x104 cells/well) were stimulated with
plate-bound anti-CD3 (clone OKT3, 1.5 mg/mL, BioLegend) and
soluble anti-CD28 (clone CD28.2, 1.5 mg/mL, BioLegend) mAb
in the absence or in the presence of cell sorted autologous control
(NKcontrol) or tumor-experienced NK cells (NKte) at different
ratios, in the absence or in the presence of a blocking anti-PD-L1
mAb (20 mg/mL, clone 29E.2A3, BioLegend). After 5 days, cells
were harvested, stained for CD3, CD56, CD8, and ZombieAqua
viability dye, and CFSE dilution was analyzed by flow cytometry.
The proliferation was normalized to the proliferation of
stimulated T cells without NK cells for each donor. Relative
proliferation was calculated as the percentage of CFSEloCD8+ T
cells in each experimental condition (with NKte or NKcontrol)
divided by the percentage of CFSEloCD8+ T cells observed in the
absence of NK cells for each donor, multiplied by 100.
Statistical Methods
Differences between data sets were analyzed with the two-sided
Student’s t-test, or with Wilcoxon or Mann-Whitney tests; one-
way ANOVA (when more than two experimental groups were
compared) or two-way ANOVA (when two variables were
analyzed), with Dunnett´s, Tukey’s or Sidak´s multiple post
hoc tests; and the correlation between two variables was
analyzed with Pearson´s coefficient using GraphPad
Prism Software.RESULTS
NK Cell Infiltration in ccRCC Patients Is
Associated With Decreased Survival
To investigate the impact of TINK on patient survival, first we
analyzed TCGA ccRCC datasets using the GEPIA2 tool. We used
a NK cell gene signature as surrogate marker of NK cell
infiltration. Kaplan-Meier analysis revealed that a higher NK
cell infiltration (NKhigh) is associated with a poor outcome, both
in terms of disease-free survival and overall survival (Figure 1).
These results suggest that TINK in ccRCC might have a
paradoxical deleterious impact on tumor growth control.
PD-L1 Is Up-Regulated in NK Cells From
ccRCC Patients
Previously, we observed that tumor-bearing mice exhibit an
increased frequency of NK cells that express the inhibitory
molecule PD-L1, and that they can limit tumor antigen-specific
CD8 T cell priming (30). As the expression of PD-L1 on humanSeptember 2021 | Volume 12 | Article 745939
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human NK cells from ccRCC patients also contain an increased
frequency of cells that express PD-L1. We analyzed the frequencyFrontiers in Immunology | www.frontiersin.org 4of TINK cells within CD45+ cells in fresh ccRCC samples by flow
cytometry and observed that ccRCC tumors are infiltrated by NK
cells, with frequencies ranging from 3.21% to 54.61%. We next
assessed the expression of PD-L1 on NK cells from peripheral
blood (PBNK) and TINK from these ccRCC patients. The
frequency of PD-L1+ NK cells and the intensity of PD-L1
expression was similar among PBNK from healthy donors
(HD) and ccRCC patients (Figure 2A). However, the
frequency of TINK that express PD-L1 and the intensity of
PD-L1 expression on these TINK was significantly higher than in
PBNK of the same patient (Figures 2B, C). PD-L1 up-regulation
could also be induced in vitro on PBNK from HD upon coculture
with the NK cell-sensitive RCC cell lines SN12c and 786-O
(Figures 2D, E). Cell contact with tumor cells was essential for
the induction of PD-L1 expression since the separation of PBMC
from SN12c and from 786-O cells by transwells prevented PD-L1
up-regulation (Figure 2F). Therefore, direct interaction with
RCC tumor cells promotes the up-regulation of PD-L1 on NK
cells that resemble NK cells detected in the tumor niche.
Tumor Recognition and PBMC-Derived
Factors Induce PD-L1 on NK Cells
To investigate the mechanisms underlying PD-L1 up-regulation
on NK cells, we cultured isolated NK cells or whole PBMC fromFIGURE 1 | The presence of a high NK cell infiltration in ccRCC is
associated with decreased survival. Kaplan-Meier curves for patients with
KIRC (n = 516) from the TCGA database. Disease-free survival (left) and
overall survival (right) of patients with high (red line) and low (blue line) NK cell
infiltration was established according to the abundance of a gene signature
that includes 10 NK cell-associated genes (NCR1, XCL1, XCL2, NCAM1,
NCR3, IL18RAP, KIR2DL4, KLRC3, KLRD1 and NCR2, as explained in
Materials and Methods). Hazard ratio (HR) for the high NK infiltration and
logrank p values are shown in the lower left of each Kaplan-Meier plot. Top
and bottom quartiles are shown.A B
D E F
C
FIGURE 2 | TINK cells from patients with ccRCC exhibit an accumulation of PD-L1+ cells and increased expression of PD-L1. (A) Frequency of PD-L1+ NK cells
(left) and expression of PD-L1 (right) on PBNK from healthy donors (HD, n=41) and ccRCC patients (n=22), assessed by flow cytometry. (B) Frequency of PD-L1+
NK cells (left) and MFI of PD-L1 (right) on PBNK and TINK from matched ccRCC patients, assessed by flow cytometry (n=17). (C) Representative zebra plots of
CD56 vs PD-L1 on PBNK and TINK from a representative ccRCC patient. (D) Frequency of PD-L1hi NK cells after culture of PBMC from HD in the absence
(Medium) or in the presence of SN12c or 786-O RCC cell lines for 48 h, assessed by flow cytometry (n=12). (E) Representative zebra plots. (F) Frequency of PD-L1hi
NK cells after culture of PBMC from HD in the absence (Medium) or in the presence of SN12c or 786-O RCC cell lines in contact or separated by transwells (Tw) for
48 h, assessed by flow cytometry (n=7). Two-sided Student´s t test (A, B); one-way ANOVA with Dunnett´s post hoc test (D, F). Data represent mean ± SEM (D, F).
ns, non-significant; *p<0.05, ***p<0.001, ****p<0.0001.September 2021 | Volume 12 | Article 745939
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effects mediated by differences in KIR receptors) for 48 h and
evaluated the frequency of PD-L1hi NK cells. We observed a
higher frequency of PD-L1hi NK cells when NK cells were
exposed to K562 tumor cells in the presence of other cells
present in PBMC, suggesting that PBMC can provide
costimulatory signals that result in a more efficient PD-L1 up-
regulation (Figures 3A, B). Nonetheless, cell contact with tumor
cells was essential for the induction of PD-L1 (Figure 3C).
Furthermore, the effect was partially dependent on NKG2D
engagement on NK cells, as NKG2D blockade interfered with
the up-regulation of PD-L1 (Figure 3C). To investigate the
nature of the PBMC-derived factors that contributed to PD-L1
up-regulation on NK cells, we cultured NK cells or NK cells in
contact with K562 cells (bottom compartment) separated by
transwells from PBMC or K562 cells and PBMC (top
compartment), as depicted in Figure 3D, and assessed the
frequency of PD-L1hi NK cells in the bottom compartment
(Figure 3E). Whereas NK cells that only sensed soluble factors
derived from PBMC and K562 cells exhibited a marginal up-
regulation of PD-L1, NK cells in contact with K562 cells that
received PBMC-derived soluble factors exhibited a minor but
significant PD-L1 up-regulation. Instead, NK cells that
experienced direct cell contact with K562 cells and sensed
K562-experienced PBMC-derived soluble factors exhibited a
marked up-regulation of PD-L1, resulting in an increased
frequency of PD-L1hi NK cells (Figure 3E). Thus, contact
between NK cells and tumor cells in cooperation with soluble
factors derived from K562-experienced PBMC strongly induce
PD-L1 expression on NK cells.Frontiers in Immunology | www.frontiersin.org 5PBMC-Derived IL-18 Enhance PD-L1
Expression on Tumor-Experienced
NK Cells
To unravel possible PBMC-derived soluble mediators involved
in PD-L1 up-regulation, we neutralized different cytokines
known to activate NK cells (IL-12, IL-15, or IL-18) with
specific mAb during PBMC and K562 cocultures and after
48 h NK cells were evaluated for PD-L1 expression. IL-18
neutralization, but not IL-12 or IL-15 neutralization, interfered
with PD-L1 up-regulation on NK cells (Figure 4A), suggesting
that IL-18 produced during tumor-stimulation of PBMC
contributes to enhance PD-L1 expression on NK cells.
Similarly, IL-18 neutralization interfered with PD-L1 up-
regulation on NK cells present in PBMC from HD cultured
with SN12c cells or with 786-O cells (Figure 4B). Accordingly,
PBMC stimulation with K562 cells, SN12c cells or 786-O cells
resulted in a significantly increased IL-18 production
(Figure 4C) and the concentration of IL-18 in the supernatant
of PBMC stimulated with K562 positively correlated with the
frequency of PD-L1hi NK cells (Figure 4D). K562-driven IL-18
production by PBMC required cell-to-cell contact as it was
prevented when PBMC were separated from K562 and NK
cells using transwells (Figure 4E). Moreover, conditioned
media from K562 cells cultured with NK cells barely induced
IL-18 secretion by PBMCs (not shown). In addition,
supplementation of NK cell cultures with IL-18 during
stimulation with K562 cells significantly increased the
expression of PD-L1 on NK cells (Figure 4F). Moreover, PD-
L1 expression was preferentially induced on IL-18Ra+ NK cells
(Figure 4G). Next, we analyzed IL-18Ra and PD-L1 expressionA B D EC
FIGURE 3 | Emergence of PD-L1hi NK cells requires contact with tumor cells and PBMC-derived soluble factors. (A) Frequency of PD-L1hi NK cells after culture of
isolated NK cells or PBMC in the absence (Medium) or in the presence of K562 cells for 48 h, assessed by flow cytometry (n=7-11). (B) Representative zebra plots.
(C) Frequency of PD-L1hi NK cells after culture of PBMC in the absence (Medium) or in the presence of K562 cells, in contact or separated by a Tw, or in the
presence of anti-NKG2D blocking mAb for 48 h, assessed by flow cytometry (n=4). (D) Experimental design used to assess the requirements for the induction of
PD-L1hi NK cells. Isolated NK cells, PBMC and K562 cells were cultured separated by Tw as indicated in the figure. (E) Frequency of PD-L1hi NK cells after culture
of isolated NK cells in the absence (Medium) or in the presence of K562 cells or PBMC together or separated by Tw, assessed by flow cytometry (n=3). Data
represent mean ± SEM. Two-way ANOVA with Sidak´s multiple comparison (A) and one-way ANOVA with Dunnett´s (C) and Tukey´s (E) posthoc. ns, non-
significant; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.September 2021 | Volume 12 | Article 745939
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with K562 cells. A higher frequency of IL-18Ra+ cells was
observed among CD56bright NK cells (Figure 4H), and the
frequency of PD-L1hi cells was higher in CD56bright NK cells
(Figure 4I). These results suggest that PD-L1 becomes
preferentially expressed on IL-18 responsive (IL-18Ra+) NK
cells. Altogether, these results identify IL-18 as a critical
cytokine that contributes to PD-L1 up-regulation on tumor-
experienced NK cells.Frontiers in Immunology | www.frontiersin.org 6Monocyte-Derived IL-18 Accounts for the
Accumulation of PD-L1hi NK Cells
As monocytes constitute the main cell population within PBMC
that can produce IL-18, we analyzed the frequency of PD-L1hi
NK cells when isolated NK cells were stimulated with K562 cells
in the presence of autologous monocytes. Monocytes
significantly increased the expression of PD-L1 on NK cells, to
the level observed when whole PBMC were cultured with K562
cells, and this effect was partially reverted by IL-18 blockadeA B
D E F G
IH
C
FIGURE 4 | IL-18 produced during tumor-stimulation of PBMC enhances PD-L1 expression on tumor-experienced NK cells. (A) Frequency of PD-L1hi NK cells after
culture of PBMC in the absence (Medium) or in the presence of K562 cells and different cytokine-neutralizing mAb for 48 h, assessed by flow cytometry (n=5).
(B) Frequency of PD-L1hi NK cells after culture of PBMC in the absence (Medium) or in the presence of SN12c cells (left) or 786-O cells (right) and in the absence or
in the presence of an anti-IL-18-neutralizing mAb for 48 h, assessed by flow cytometry (n=4). (C), IL-18 concentration in supernatants of PBMC cultured in the
absence (Medium) or presence of K562 cells (n=13), SN12c cells (n=4) or 786-O cells (n=4), assessed by ELISA. (D) Correlation between the concentration of IL-18
detected in the culture supernatants of PBMC stimulated with K562 cells and the frequency of PD-L1hi NK cells (n=13). (E) IL-18 concentration in supernatants of
PBMC cultured in contact with K562 cells and separated from isolated NK cells by Tw (left) or PBMC separated from isolated NK cells and K562 cells by Tw (right),
assessed by ELISA (n=7). (F) Frequency of PD-L1hi NK cells after culture of isolated NK cells in the absence (Medium) or in the presence of IL-18, K562 cells or
K562 cells and IL-18 (K562+IL-18) for 48 h, assessed by flow cytometry (n=10). (G) Frequency of PD-L1hi cells detected in IL-18Ra+ (red) and IL-18Ra- NK cells
(blue) after stimulation of PBMC with K562 cells for 48 h, assessed by flow cytometry (n=3). A representative histogram is shown. (H) Frequency of IL-18Ra+ cells
among CD56dim and CD56bright NK cells after culture of PBMC in the presence of K562 cells for 48 h (n=3). (I) Frequency of PD-L1hi cells among CD56dim and
CD56bright NK cells after culture of PBMC in the presence of K562 cells for 48 h (n=8). Data represent mean ± SEM. One-way ANOVA with Dunnett´s (A, B) and
Tukey´s (F) post hoc test, two-sided Student´s t test (C, E, G–I) and Pearson´s correlation (D). ns, non-significant; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.September 2021 | Volume 12 | Article 745939
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K562 cells (or RCC cell lines, not shown) produced similar
amounts of IL-18 than PBMC cultured with tumor cells
(Figure 5B), and separation of monocytes from NK cells and
tumor cells by transwells abrogated IL-18 secretion (not shown).
These results support the idea that monocytes sense the presence
of tumor cells through cell contact and respond secreting IL-18,
which in turn enhance PD-L1 expression on tumor-stimulated
NK cells.
Features of PD-L1hi NK Cells
To characterize the phenotype and function of PD-L1hi NK cells,
PBMC from HD were cultured with K562 cells for 48 h, and the
phenotype and effector function of PD-L1hi versus PD-L1-/low
NK cells was analyzed. PD-L1hi NK cells exhibited a higher
frequency of CD25+ (Figure 6A), CD69+ (Figure 6B), TRAIL+
(Figure 6C) and FasL+ cells (Figure 6D) compared to PD-L1-/low
NK cells, suggesting that PD-L1 is preferentially expressed on
NK cells that have undergone activation and acquired tissue
homing and cytotoxicity effector molecules. In addition, PD-L1hi
NK cells also exhibited higher degranulation (CD107a
expression) and IFN-g production capacity than PD-L1-/low
NK cells (Figures 6E, F), confirming that PD-L1hi NK cells, in
opposition to PD-L1-/low NK cells, display an activated
phenotype and are highly functional.
Tumor-Experienced NK Cells Limit CD8+
T Cell Proliferation Through PD-L1
As the PD-1/PD-L1 axis constitutes a major co-inhibitory
pathway in T cells, we wondered whether PD-L1hi NK cells
contribute to constrain CD8+ T cell proliferation. Therefore, we
performed T cell proliferation assays in the presence of tumor-
experienced autologous NK cells enriched in PD-L1hi NK cells
(NKte) or naïve NK cells (NKcontrol), following the experimental
design depicted in Figure 7A. We stimulated CFSE-labeled T
cells with anti-CD3 and anti-CD28 mAb in the absence or in the
presence of growing numbers of NKcontrol or NKte and after 5 d
we assessed the proliferation of CD8+ T cells (CFSE dilution).Frontiers in Immunology | www.frontiersin.org 7The extent of CD8+ T cell proliferation was minimally affected by
NKcontrol cells but decreased as the proportion of NKte cells in the
cultures increased (Figure 7B). Also, PD-L1 blockade restored
CD8+ T cell proliferation, indicating that the effect was PD-L1-
dependent (Figure 7C). These results indicate that tumor-
experienced NK cells can limit CD8+ T cell expansion through
PD-L1 engagement.DISCUSSION
NK cells display anti-tumor activity and a higher natural
cytotoxic activity in peripheral blood has been associated with
lower tumor incidence (4). However, a regulatory role for NK
cells has been described during viral infection (14–17),
transplantation (18) and autoimmunity (19). We recently
demonstrated that in mice NK cells also can acquire a
regulatory phenotype characterized by a tumor-induced up-
regulation of PD-L1 (30). Therefore, although a dual role for
NK cells is emerging, the impact of this dual role in tumor
progression remains ill-defined. To get a first insight into this
subject, we analyzed publicly available RNAseq and survival data
from ccRCC patients deposited at TCGA. As an estimate of NK
cell infiltration, we used a gene signature for NK cells based on
previously published NK cell signatures (42–45) that includes 10
NK cell-associated genes not expressed or weakly expressed on
CD8+ T cells (NCR1, XCL1, XCL2, NCAM1, NCR3, IL18RAP,
KIR2DL4, KLRC3, KLRD1 and NCR2). Patients with a high NK
cell infiltration (assessed as presence of a high expression of NK
cell signature genes) exhibited a worse outcome than the group of
patients with a low NK cell infiltration, which is in accordance
with previous reports (46). A possibility that explains this finding
is that TINK in ccRCCmight facilitate tumor growth. However, it
is also possible that tumors that developed more proficient
strategies to subvert NK cell effector function exhibit higher
tumor growth, resulting in lower disease-free and overall
survival. TINK often are dysfunctional and display phenotypic
alterations compared to NK cells from blood or from peritumoral
tissue in different cancer types (8, 9, 11), including RCC (10, 12,
47). Using a mouse model, we previously demonstrated that
TINK express PD-L1 and inhibit anti-tumor T cell responses. In
the present work, we observed that TINK from human ccRCC
patients exhibit an increased frequency of PD-L1+ cells and
display an enhanced expression of PD-L1 compared to PBNK.
Moreover, two RCC cell lines, one corresponding to a ccRCC
(786-O), promoted the appearance of PD-L1hi NK cells in PBMC
from healthy donors. A large meta-analysis showed that PD-L1
expression in RCC tumor cells is associated with poorer overall
survival (48), while PD-L1 expression on tumor-infiltrating
immune cells is associated with poor prognosis in ccRCC
patients (49). Therefore, we aimed at dissecting the mechanisms
underlying the emergence of PD-L1hi NK cells. We demonstrated
that PBMC-derived factors, more precisely IL-18 produced by
monocytes, plus NK cell-tumor cell contact that involves NKG2D
were necessary to induce the up-regulation of PD-L1 on NK cells.
Because IL-18 neutralization only partially blocked PD-L1 up-
regulation on NK cells, suggests the participation of other solubleA B
FIGURE 5 | Monocyte-derived IL-18 induces PD-L1 expression on tumor-
experienced NK cells. (A) Frequency of PD-L1hi NK cells after culture of
PBMC in the absence or in the presence of K562, isolated NK cells in the
presence of K562 cells and/or autologous monocytes (Mo), in the absence or
in the presence of an anti-IL-18 neutralizing mAb for 48 h, assessed by flow
cytometry. (B) concentration of IL-18 in supernatants of the cultures,
assessed by ELISA. Data represent mean ± SEM, (n=4). One-way ANOVA
with Dunnett´s post hoc test. ns, non-significant; *p<0.05, **p<0.01.September 2021 | Volume 12 | Article 745939
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FIGURE 6 | PD-L1hi NK cells exhibit an activated phenotype and express higher cytotoxic mediators. Frequency of CD25+ cells (A), CD69+ cells (B) TRAIL+ cells
(C), FasL+ cells (D), CD107a+ cells (E) and IFN-g + cells (F) detected in PD-L1hi (red) and PD-L1-/low NK cells (blue) after stimulation of PBMC with K562 cells for
48 h, assessed by flow cytometry (n=7). A representative histogram for each marker is shown. Two-sided Student´s t test **p<0.01, ***p<0.001, ****p<0.0001.A
B C
FIGURE 7 | Tumor-experienced NK cells inhibit CD8+ T cell proliferation through PD-L1. (A) Experimental design used to generate control NK cells (NKcontrol) and
tumor-experienced NK cells enriched in PD-L1hi cells (NKte) to investigate their effect on T cell proliferation. (B) Relative proliferation of CD8
+ T cells analyzed by
CFSE dilution after stimulation with anti-CD3/anti-CD28 mAb and cultured with increasing numbers of autologous NKcontrol or NKte. (C) Relative proliferation of CD8
+
T cells analyzed by CFSE dilution after stimulation with anti-CD3/anti-CD28 mAb in the absence or in the presence of autologous NKcontrol or NKte in the absence or
in the presence of an anti-PD-L1 blocking mAb. Representative histograms showing CFSE dilution in live CD3+CD8+CD56- cells are shown (n=3). Data represent
mean ± SEM. Two-way ANOVA with Sidak´s post hoc test (B) and one-way ANOVA and Tukey´s post hoc test (C) *p<0.05, **p<0.01, *** p<0.001.Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 7459398
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IL-18-responsive (IL-18Ra+) NK cells supports our conclusions.
IFN-g is a positive regulator for PD-L1 expression in multiple cell
types (32, 50). However, PD-L1 expression on NK cells remained
unchanged when PBMC were stimulated with K562 cells in the
presence of an anti-IFN-g receptor blocking mAb or an
anti-IFN-g neutralizing mAb, or when isolated NK cells were
stimulated with IFN-g (not shown). Instead, our results indicate
that IL-18 produced by monocytes represents the main factor that
enhanced PD-L1 expression in tumor-stimulated NK cells. These
findings might indicate that PD-L1hi NK cells may even appear
when NK cell and T cell-derived IFN-g production is waned
because of different tumor-escape mechanisms. IL-18 is a
cytokine with pro-inflammatory properties, involved in
stimulation of NK cells and Th1-biased immune responses that
are crucial for anti-tumor immunity (51). However, IL-18 also has
a dual role as the presence of high amounts of IL-18 in serum of
patients with tumors of different etiology, including RCC, is
associated with disease progression and aggressiveness, and
correlates with advanced tumor stage, worsened outcome and
shorter overall survival (52–54). In this scenario, IL-18-driven
emergence of PD-L1hi NK cells might be part of the tumor-
promoting effects of this cytokine.
Although PD-L1 expressed on tumor cells plays a relevant
role in attenuating anti-tumor immunity, different studies using
preclinical mouse models showed that PD-L1 expression on non-
tumor cells plays non-overlapping roles in the suppression of
anti-tumor T cell responses and contributes to tumor escape (36,
37). Moreover, the efficacy of anti-PD-L1 therapy relies partially
on PD-L1 expression on non-tumor cells (38, 39, 55).
Accordingly, our results showing that ccRCC-infiltrating NK
cells display an increased frequency of PD-L1hi NK cells, and that
tumor-experienced NK cells enriched in PD-L1hi NK cells can
inhibit CD8+ T cell proliferation through PD-L1, suggest that NK
cells also might be targeted during immune checkpoint
treatment of cancer patients with anti-PD-1/PD-L1 mAb.
Accordingly, the presence of PD-L1+ NK cells in blood of
acute myeloid leukemia patients was recently reported, and
treatment with atezolizumab, a humanized anti-PD-L1 mAb,
increased the effector functions of PD-L1+ NK cells (56). In
addition, as PD-1 can be expressed on a subset of NK cells, as
observed in CMV-infected and in cancer patients (57), it is also
possible that PD-L1hi NK cells might display a regulatory activity
on PD-1+ NK cells, either via cis or trans interaction.
Our results showing that in vitro generated PD-L1hi NK cells
display enhanced effector functions and an activated phenotype
might contrast with our initial observation that high TINK
infiltration correlates with a worsened outcome. However, as
NK cell activation occurs early after encounter with tumors, and
PD-L1 up-regulation is observed later, peaking at 48 h, it is
conceivable that PD-L1 becomes up-regulated preferentially on
activated NK cells as part of a homeostatic program. Also,
analysis of TINK from sarcoma and breast tumor patients,
demonstrated co-expression of multiple immune checkpoints
including PD-L1, CD73, TIM-3, LAG-3, VISTA and PD-1 (58).
These data indicate that chronically stimulated TINK acquire
features of exhausted cells, in opposition to NK cells stimulatedFrontiers in Immunology | www.frontiersin.org 9in vitro for only 48 h as we used in this work. Moreover, the
immunosuppressive tumor microenvironment also operates on
NK cells, rendering them exhausted and dysfunctional.
CD8+ T cells are critical for tumor elimination and the presence
of tumor-infiltrating CD8+ T cells has a positive prognostic value in
patients with different cancer types (59). Moreover, in ccRCC
patients a higher proliferative activity of tumor-infiltrating CD8+
T cells is associated with longer survival (60). Our results showing
that tumor-experienced NK cells were able to inhibit CD8+ T cell
proliferation could explain why a high infiltration of NK cells is
associated with reduced survival.
In summary, tumor recognition, in cooperation with
monocyte-derived IL-18, induce the expression of PD-L1 on
NK cells, resulting in an enrichment in PD-L1hi NK cells that in
turn limit CD8+ T cell proliferation in a PD-L1-dependent
manner. Therefore, the clinical response observed in several
tumor types, including ccRCC, after therapeutic targeting the
PD-1/PD-L1 axis using specific checkpoint inhibitors might be
partially dependent on PD-L1 blockade on TINK.DATA AVAILABILITY STATEMENT
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Recruited Into Lymph Nodes Inhibit Alloreactive T-Cell Activation Through
Perforin-Mediated Killing of Donor Allogeneic Dendritic Cells. Blood (2008)
112:661–71. doi: 10.1182/blood-2007-10-120089
19. Ehlers M, Papewalis C, Stenzel W, Jacobs B, Meyer KL, Deenen R, et al.
Immunoregulatory Natural Killer Cells Suppress Autoimmunity by Down-
Regulating Antigen-Specific CD8+ T Cells in Mice. Endocrinology (2012)
153:4367–79. doi: 10.1210/en.2012-1247
20. Rabinovich BA, Li J, Shannon J, Hurren R, Chalupny J, CosmanD, et al. Activated,
But Not Resting, T Cells Can Be Recognized and Killed by Syngeneic NK Cells.
J Immunol Baltim Md 1950 (2003) 170:3572–6. doi: 10.4049/jimmunol.170.7.3572
21. Cerboni C, Zingoni A, Cippitelli M, Piccoli M, Frati L, Santoni A. Antigen-
Activated Human T Lymphocytes Express Cell-Surface NKG2D Ligands via
an ATM/ATR-Dependent Mechanism and Become Susceptible to Autologous
NK- Cell Lysis. Blood (2007) 110:606–15. doi: 10.1182/blood-2006-10-052720
22. Soderquest K, Walzer T, Zafirova B, Klavinskis LS, Polić B, Vivier E, et al.
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